NCT03318562View on ClinicalTrials.gov

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 21, 2017

Primary Completion Date

July 5, 2018

Study Completion Date

January 22, 2019

Conditions
Triple Negative Breast CancerHepatocellular Carcinoma
Interventions
DRUG

eFT508

200 mg eFT508 dosed BID for 3 week cycles

Trial Locations (2)

64131

Kansas City Research Institute, Kansas City

91010

City of Hope, Duarte

Sponsors
All Listed Sponsors
lead

Effector Therapeutics

INDUSTRY